BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology

BioCryst Pharmaceuticals BCRX today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K. BioCryst's two posters presented today report efficacy findings from the Company's Phase 2 study evaluating BCX4208 alone and in combination with allopurinol and pooled safety results from this combination study and the Company's Phase 2 BCX4208 monotherapy study. In both these studies, BCX4208 was administered once-daily for 3-weeks in gout patients. Poster THU0011 titled “BCX4208 Shows Synergistic Reductions in Serum Uric Acid in Gout Patients When Combined with Allopurinol” by A. Hollister et al. additionally concludes that the combination of BCX4208 and allopurinol brought a larger proportion of gout patients to serum uric acid level below 6 mg/dL than allopurinol alone. There were no pharmacokinetic drug-drug interactions between BCX4208 and either allopurinol or its active metabolite, oxypurinol.